ImportantJNJ
Explain this story: BofA Securities Raises Price Target on Johnson & Johnson to $278 From $263, Keeps Neutral Rating
BofA Securities has increased its price target for Johnson & Johnson (JNJ) to $278 from $263, while maintaining a neutral rating on the stock. This adjustment reflects the analyst's updated valuation for the pharmaceutical and medical device giant. The article also briefly mentions JNJ's current stock performance and upcoming earnings release.
Otherwww.marketscreener.comSector and industry: HealthcareDrug ManufacturersTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
BofA Securities has increased its price target for Johnson & Johnson (JNJ) to $278 from $263, while maintaining a neutral rating on the stock. This adjustment reflects the analyst's updated valuation for the pharmaceutical and medical device giant. The article also briefly mentions JNJ's current stock performance and upcoming earnings release.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Published Sep 29, 2026, 10:52 ET · on this site +1h 56m